| A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) (NCT06581198) | Novartis Pharmaceuticals | 2024-09-04 |
| Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer (NCT06517719) | Novartis Pharmaceuticals | 2024-09-04 |
| A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease (NCT06546670) | Novartis Pharmaceuticals | 2024-08-15 |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. (NCT06247995) | Novartis Pharmaceuticals | 2024-08-14 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib (NCT06401356) | Novartis Pharmaceuticals | 2024-08-13 |
| Iptacopan in Patients With ANCA Associated Vasculitis (NCT06388941) | Novartis Pharmaceuticals | 2024-08-05 |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. (NCT06517758) | Novartis Pharmaceuticals | 2024-07-31 |
| ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients (NCT06345157) | Novartis Pharmaceuticals | 2024-07-30 |
| NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (NCT06379217) | Novartis Pharmaceuticals | 2024-07-29 |
| Revolade Tablets Specified Drug-use Survey (NCT06287268) | Novartis Pharmaceuticals | 2024-07-17 |
| Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction (NCT06372925) | Novartis Pharmaceuticals | 2024-07-09 |
| Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease (NCT06462469) | Novartis Pharmaceuticals | 2024-07-04 |
| Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease (NCT06293365) | Novartis Pharmaceuticals | 2024-07-02 |
| Kesimpta Pregnancy and Infant Safety Study Using Real World Data (NCT06156683) | Novartis Pharmaceuticals | 2024-06-30 |
| A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease. (NCT06431763) | Novartis Pharmaceuticals | 2024-06-21 |
| Home Reported Outcomes in PNH (NCT06411626) | Novartis Pharmaceuticals | 2024-06-11 |
| A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany (NCT06991608) | Novartis Pharmaceuticals | 2024-06-11 |
| Migraine Survey in Gulf Region (NCT06237062) | Novartis Pharmaceuticals | 2024-06-05 |
| A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer (NCT07086196) | Novartis Pharmaceuticals | 2024-05-30 |
| Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma (NCT05739942) | Novartis Pharmaceuticals | 2024-05-15 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS (NCT05795140) | Novartis Pharmaceuticals | 2024-05-08 |
| A Study of Real-world Outcomes Among Patients Treated With Ribociclib (NCT07148505) | Novartis Pharmaceuticals | 2024-04-24 |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD (NCT06267560) | Novartis Pharmaceuticals | 2024-04-24 |
| A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia (NCT07168694) | Novartis Pharmaceuticals | 2024-04-16 |
| Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) (NCT06155500) | Novartis Pharmaceuticals | 2024-04-16 |
| A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients (NCT07151820) | Novartis Pharmaceuticals | 2024-04-08 |
| Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy (NCT06236061) | Novartis Pharmaceuticals | 2024-04-08 |
| Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function (NCT06004661) | Novartis Pharmaceuticals | 2024-04-04 |
| Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal (NCT07223476) | Novartis Pharmaceuticals | 2024-03-29 |
| Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States (NCT07214857) | Novartis Pharmaceuticals | 2024-03-29 |
| Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR (NCT06130540) | Novartis Pharmaceuticals | 2024-03-27 |
| A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan (NCT06240741) | Novartis Pharmaceuticals | 2024-03-21 |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (NCT05939414) | Novartis Pharmaceuticals | 2024-03-12 |
| Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria (NCT05842954) | Novartis Pharmaceuticals | 2024-03-07 |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis (NCT05646381) | Novartis Pharmaceuticals | 2024-03-07 |
| A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (NCT06075758) | Novartis Pharmaceuticals | 2024-03-07 |
| Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France (NCT06092879) | Novartis Pharmaceuticals | 2024-03-06 |
| Specified Drug-use Survey of Leqvio for s.c. Injection. (NCT06275724) | Novartis Pharmaceuticals | 2024-03-04 |
| A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure (NCT07217106) | Novartis Pharmaceuticals | 2024-03-03 |
| Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (NCT05935215) | Novartis Pharmaceuticals | 2024-02-28 |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (NCT05827081) | Novartis Pharmaceuticals | 2024-02-28 |
| Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment (NCT07188428) | Novartis Pharmaceuticals | 2024-02-27 |
| A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice (NCT06251986) | Novartis Pharmaceuticals | 2024-02-26 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (NCT06006559) | Novartis Pharmaceuticals | 2024-02-20 |
| A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China (NCT06053801) | Novartis Pharmaceuticals | 2024-02-16 |
| A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (NCT06097663) | Novartis Pharmaceuticals | 2024-02-15 |
| A Canadian Study of Persistence on Ofatumumab Using Patient Support Program Data (NCT06854341) | Novartis Pharmaceuticals | 2024-02-09 |
| Special Drug Use-results Surveillance of Tafinlar/Mekinist (NCT06262919) | Novartis Pharmaceuticals | 2024-02-09 |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (NCT05868629) | Novartis Pharmaceuticals | 2024-02-06 |
| Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting (NCT07374120) | Novartis Pharmaceuticals | 2024-02-01 |
| Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery (NCT05413980) | Novartis Pharmaceuticals | 2024-01-27 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2) (NCT07235033) | Novartis Pharmaceuticals | 2024-01-23 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (NCT07235020) | Novartis Pharmaceuticals | 2024-01-23 |
| A Study of the Epidemiology and Hospital Management of Patients With PROS in France (NCT07222423) | Novartis Pharmaceuticals | 2024-01-15 |
| Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials (NCT06215287) | Novartis Pharmaceuticals | 2024-01-12 |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (NCT05849298) | Novartis Pharmaceuticals | 2024-01-03 |
| Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis (NCT06142357) | Novartis Pharmaceuticals | 2023-12-29 |
| A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia (NCT06148506) | Novartis Pharmaceuticals | 2023-12-28 |
| Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France (NCT06157086) | Novartis Pharmaceuticals | 2023-12-21 |
| A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure (NCT06142383) | Novartis Pharmaceuticals | 2023-12-12 |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines (NCT05976243) | Novartis Pharmaceuticals | 2023-12-07 |
| WOE of Anti-CD20 Therapies (NCT06121349) | Novartis Pharmaceuticals | 2023-12-04 |
| A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study (NCT06149104) | Novartis Pharmaceuticals | 2023-12-04 |
| Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study (NCT05809986) | Novartis Pharmaceuticals | 2023-11-27 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. (NCT05948943) | Novartis Pharmaceuticals | 2023-11-24 |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies (NCT05541341) | Novartis Pharmaceuticals | 2023-11-23 |
| Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. (NCT06042478) | Novartis Pharmaceuticals | 2023-11-15 |
| Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (NCT05983198) | Novartis Pharmaceuticals | 2023-11-07 |
| A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients (NCT06897657) | Novartis Pharmaceuticals | 2023-11-06 |
| In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease (NCT05974345) | Novartis Pharmaceuticals | 2023-11-03 |
| A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NCT05985915) | Novartis Pharmaceuticals | 2023-10-27 |
| Effectiveness of Ofatumumab in Real-world Practice (NCT06760624) | Novartis Pharmaceuticals | 2023-10-24 |
| A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients (NCT07376265) | Novartis Pharmaceuticals | 2023-10-20 |
| A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (NCT06031844) | Novartis Pharmaceuticals | 2023-10-16 |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (NCT05977322) | Novartis Pharmaceuticals | 2023-10-06 |
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN (NCT05755386) | Novartis Pharmaceuticals | 2023-10-02 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (NCT05888493) | Novartis Pharmaceuticals | 2023-10-02 |
| An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (NCT05900141) | Novartis Pharmaceuticals | 2023-09-29 |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer (NCT05809895) | Novartis Pharmaceuticals | 2023-09-15 |
| An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer (NCT07072013) | Novartis Pharmaceuticals | 2023-09-08 |
| Special Drug Use Surveillance of Entresto Tablets (Hypertension) (NCT05976230) | Novartis Pharmaceuticals | 2023-09-04 |
| Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus (NCT05272059) | Novartis Pharmaceuticals | 2023-09-01 |
| An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) (NCT06254482) | Novartis Pharmaceuticals | 2023-08-25 |
| A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies (NCT05885555) | Novartis Pharmaceuticals | 2023-08-16 |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer (NCT05803941) | Novartis Pharmaceuticals | 2023-08-14 |
| Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (NCT05722522) | Novartis Pharmaceuticals | 2023-08-10 |
| Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. (NCT05921994) | Novartis Pharmaceuticals | 2023-08-10 |
| Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (NCT05758415) | Novartis Pharmaceuticals | 2023-08-02 |
| Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease (NCT05857748) | Novartis Pharmaceuticals | 2023-07-31 |
| Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. (NCT05791097) | Novartis Pharmaceuticals | 2023-07-28 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy (NCT05834738) | Novartis Pharmaceuticals | 2023-07-20 |
| Asciminib RMP Study (NCT05943522) | Novartis Pharmaceuticals | 2023-07-19 |
| Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol. (NCT05888103) | Novartis Pharmaceuticals | 2023-07-11 |
| 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up (NCT05677451) | Novartis Pharmaceuticals | 2023-07-11 |
| Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years (NCT05776888) | Novartis Pharmaceuticals | 2023-07-10 |
| A Study of Zigakibart in Adults With IgA Nephropathy (NCT05852938) | Novartis Pharmaceuticals | 2023-07-06 |
| Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. (NCT05838768) | Novartis Pharmaceuticals | 2023-06-27 |
| A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617 (NCT07450157) | Novartis Pharmaceuticals | 2023-06-23 |
| A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia (NCT07415083) | Novartis Pharmaceuticals | 2023-06-21 |
| A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting (NCT04967248) | Novartis Pharmaceuticals | 2023-06-21 |